ArticleThe European respiratory journal2023
Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort.
Article in The European respiratory journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 32 citations in OpenAlex.
- Assessment of Thrombotic Risk in Patients with Tuberculosis and SARS-CoV-2 Coinfection: A Retrospective Study.Diagnostics (Basel, Switzerland) · 2026Article
- Global excess tuberculosis mortality during COVID-19: a country-level modeling study of policy and development correlates.BMC public health · 2025Article
- Tuberculosis treatment failure: what are the risk factors? A comprehensive literature review.Multidisciplinary respiratory medicine · 2025Article
- Short- and long-term increased risk of all-cause mortality in a tuberculosis cohort attributed to SARS-CoV-2 infection: a time-dependent survival analysis in Chile.Lancet regional health. Americas · 2025Article
- The Temporal Trends of Mortality Due to Tuberculosis in Brazil: Tracing the Coronavirus Disease 2019 (COVID-19) Pandemic's Effect Through a Bayesian Approach and Unmasking Disparities.Microorganisms · 2025Article
- Suppressing Mycobacterium tuberculosis virulence and drug resistance by targeting Eis protein through computational drug discovery.Molecular diversity · 2025Article
- Prevalence and risk factors of COVID-19 co-infection in TB patients.IJTLD open · 2025Article
- Clinical outcomes of patients with coronavirus disease 2019 and active tuberculosis co-infection in Beijing China: A retrospective single-center descriptive study.Infectious medicine · 2025Article
- Impact of Severity of COVID-19 in TB Disease Patients: Experience from an Italian Infectious Disease Referral Hospital.Infectious disease reports · 2025Article
- COVID-19, tuberculosis, and HIV triad: a prospective observational study in ambulatory patients in Kenya, Uganda, and South Africa.PLOS global public health · 2025Article
- Advancing the fight against tuberculosis: integrating innovation and public health in diagnosis, treatment, vaccine development, and implementation science.Frontiers in medicine · 2025Review
- Assessment of the impact of COVID-19 on tuberculosis care at a tertiary hospital: integrating lessons from COVID-19 learned.Frontiers in public health · 2025Article
- Mycobacterium tuberculosis growth inhibition by peripheral blood mononuclear cells from household contacts is not affected by previous SARS-CoV-2 infection.Gates open research · 2025Article
- Viewpoint on WHO implementation guidance on tuberculosis infection prevention and control.The European respiratory journal · 2024Article
- Trends and annual percentage changes in tuberculosis mortality estimated by Joinpoint regression and age-period-cohort analyses, Taiwan, 1978-2022.Scientific reports · 2024Article
- Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021.The Lancet. Infectious diseases · 2024Article
- Severe outcomes among adults with TB during COVID-19.IJTLD open · 2024Article
- Augmenting Radiological Diagnostics with AI for Tuberculosis and COVID-19 Disease Detection: Deep Learning Detection of Chest Radiographs.Diagnostics (Basel, Switzerland) · 2024Article
- Operational research as a mechanism to improve treatment outcomes for drug-resistant TB in the WHO European Region.IJTLD open · 2024Article
- Impact of Tuberculosis on Disease Severity and Viral Shedding Duration in COVID-19 Patients.Viruses · 2024Article
Corrections and comments
- Commented on by
Authors and funding
177 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLongitudinal cohort data of patients with tuberculosis (TB) and coronavirus disease 2019 (COVID-19) are lacking. In our global study, we describe long-term outcomes of patients affected by TB and COVID-19.
methodsWe collected data from 174 centres in 31 countries on all patients affected by COVID-19 and TB between 1 March 2020 and 30 September 2022. Patients were followed-up until cure, death or end of cohort time. All patients had TB and COVID-19; for analysis purposes, deaths were attributed to TB, COVID-19 or both. Survival analysis was performed using Cox proportional risk-regression models, and the log-rank test was used to compare survival and mortality attributed to TB, COVID-19 or both.
resultsOverall, 788 patients with COVID-19 and TB (active or sequelae) were recruited from 31 countries, and 10.8% (n=85) died during the observation period. Survival was significantly lower among patients whose death was attributed to TB and COVID-19
conclusionsIn our global cohort, death was the outcome in >10% of patients with TB and COVID-19. A range of demographic and clinical predictors are associated with adverse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.